Study study type
PathologyT1T0Patientssample sizesROB Results

la/mBC - HR-positive - 2nd line (L2) breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2)

versus fulvestrant
palbociclib plus fulvestrant
FLIPPER, 2021
  NCT02690480		RCTla/mBC - HR-positive - 2nd line (L2)palbociclib plus fulvestrantplacebo plus fulvestrantPostmenauposal women with HR-positive and HER-negative advanced breast cancer94 / 95low
 suggested
  • suggested 45 % decrease in progression or deaths (PFS) (PE)
PALOMA-3, 2016
  NCT01942135		RCTla/mBC - HR-positive - 2nd line (L2)palbociclib plus fulvestrantplacebo plus fulvestrantEligible patients were pre- or post menopausal with breast cancer and histologic or cytologicconfirmation of recurrent local or distant disease progression during or within 12 months of completion of adjuvant endocrinetherapy or while receiving or within 1 month after receivingendocrine therapy for MBC347 / 174low
 conclusif
  • inconclusive 19 % decrease in deaths (OS) (PE)
  • demonstrated 58 % decrease in progression or deaths (PFS) (PE)

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons